Ensysce生物科学公司在2025年第3季度损失410万美元,收入下降至120万美元,原因是定单时间和延迟发射。 Ensysce Biosciences lost $4.1 million in Q3 2025, saw revenue drop to $1.2 million, citing order timing and delayed launches.

Ensysce Biosciences报告了2025年第三季度的财务结果,显示净损失410万美元,即每股14美元,而去年同期净损失380万美元,即每股13美元。 Ensysce Biosciences reported third quarter 2025 financial results, disclosing a net loss of $4.1 million, or $0.14 per share, compared to a net loss of $3.8 million, or $0.13 per share, in the same period last year. 该公司该季度的收入为120万美元,比上一年季度的140万美元有所减少。 The company's revenue for the quarter was $1.2 million, a decrease from $1.4 million in the prior-year quarter. 预测将收入下降归因于客户定单的时间安排和产品发布延误。 Ensysce attributed the decline in revenue to timing of customer orders and delays in product launches. 截至本季度末,现金和现金等价物共计1 150万美元。 Cash and cash equivalents at the end of the quarter totaled $11.5 million. 该公司说,它仍然侧重于推进其诊断平台和扩大商业化工作。 The company said it remains focused on advancing its diagnostic platforms and expanding commercialization efforts.